Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study
Annick Moens, Marc Ferrante(Universitair Ziekenhuis Leuven), Wouter Van Moerkercke, Stéphane Nancey, Ariella Bar‐Gil Shitrit, Anneleen Van Hootegem, Séverine Vermeire(KU Leuven), Jochen Nijs(Tenneco (Belgium)), Peter Bossuyt(Imelda Hospital), Frank Hoentjen(Radboud University Nijmegen), Anneline Cremer, Daniel C. Baumgart(University of Alberta), Evelien Humblet, Jean‐François Rahier(CHU Dinant Godinne UCL Namur), Édouard Louis(Centre Hospitalier Universitaire de Liège), Carl Eriksson, A Posen, Zoran Milenković, C. Janneke van der Woude(Radboud University Nijmegen), Juliette Sheridan(St. Vincent's University Hospital), C. Gilletta de Saint-Joseph, Thomas Krause, S Dewit, Elisabeth Macken(Province of Antwerp), Mette Julsgaard(Aarhus University Hospital)
Cited by 137
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k